Nomura Value Fund, a series of Delaware Group Equity Funds II on Abbott Laboratories

The fund initiated Abbott after the shares fell roughly 35% from their 2025 high and reached what it described as a 10-year-low valuation. Abbott provides diversified exposure across medical devices, diagnostics, nutrition and pharmaceuticals. The team judged that the depressed valuation created a compelling long-term risk-reward opportunity. The thesis is primarily valuation-driven and rests on buying a high-quality healthcare franchise at an unusually discounted multiple.